Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning: a Phase II Randomized Study From the Belgian Hematology Society (BHS) (HLA)

  • End date
    Nov 1, 2038
  • participants needed
  • sponsor
    University of Liege
Updated on 28 October 2022
chronic myeloid leukemia
stem cell transplantation
myeloid leukemia
lymphoid leukemia
hematologic malignancy
blast crisis
chronic lymphocytic leukemia
myelodysplastic syndromes
multiple myeloma
hodgkin's disease
cell transplantation
transplant conditioning
antithymocyte globulin
myeloproliferative syndromes
white blood cells


The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized study).


This study is a multicenter, randomized, open-label, phase II study pick-a-winner study, comparing 2 conditioning regimens. A total of 114 eligible patients with HLA-matched donors will be randomized 1:1 between the FM-PTCy arm and the FM-ATG arm, with stratification for donor type (related or unrelated). The recruitment period is 3 years with a 5-year follow-up plus a 10-year additional long-term follow-up (for GVHD status, disease status, second malignancy and QOL). The whole study will be completed within 18 years.

Condition Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission, Myeloproliferative Syndrome, Myeloproliferative Disorder, Acute Lymphoid Leukemia in Remission, Multiple Myeloma, Chronic Lymphoid Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma
Treatment melphalan, Fludarabine, Thymoglobulin, Cyclophosphamid
Clinical Study IdentifierNCT03852407
SponsorUniversity of Liege
Last Modified on28 October 2022


Yes No Not Sure

Inclusion Criteria

Patients V.1.1. Diseases
Hematological malignancies confirmed histologically
AML in morphological CR or not in morphological CR but not rapidly progressing (i.e. no need to give treatments such as hydroxyurea to maintain WBC count < 10 000 x109/mL)
CML in CP or AP
MPD not in blast crisis
MDS/MPD overlap
Multiple myeloma
Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease)
Hodgkin's disease with chemosensitive disease or responding to checkpoint inhibitors
Clinical situations
• Theoretical indication for a standard allo-transplant, but not feasible
Age > 50 yrs
Unacceptable end organ performance
The physician's decision
The patient's decision
Underlying 'lower risk' disease, for which Reduced Intensity Conditioning is preferred (eg CLL, MCL)
Other inclusion criteria
Male or female; fertile patients must use a reliable contraception method
Age 18-75 yrs (children of any age are not allowed in the protocol)
Informed consent given by patient or his/her guardian if indicated
Male or female
Any age
Human Leukocyte Antigen (HLA)-identical sibling donor or 10 of 10 (HLA-A, -B, -C, -DRB1, and -DQB1) HLA allele matched unrelated donor
Weight > 15 Kg (because of leukapheresis)
Fulfills criteria for allogeneic Peripheral Blood Stem Cell (PBSC) donation according to standard procedures
Informed consent given by donor or his/her guardian if indicated, as per donor center standard procedures

Exclusion Criteria

Any condition not fulfilling inclusion criteria
Human Immunodeficiency Virus positive
Non-hematological malignancy(ies) (except non-melanoma skin cancer) active < 3 years before Hematopoietic Cell Transplantation (HCT)
Life expectancy severely limited by disease other than malignancy
Central Nervous System involvement with disease refractory to intrathecal chemotherapy
Terminal organ failure, except for renal failure (dialysis acceptable)
Cardiac: Symptomatic coronary artery disease; ejection fraction <40%; uncontrolled arrhythmia, uncontrolled hypertension
Pulmonary: Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)< 40% and/or receiving supplementary continuous oxygen, Forced Expiratory Volume in 1 Second (FEV1)< 40%
Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin >3 mg/dL, and symptomatic biliary disease
Uncontrolled infection
Karnofsky Performance Score <70%
Patient is a fertile man or woman who is unwilling to use contraceptive techniques during and for 12 months following treatment
Patient is a female who is pregnant or breastfeeding
Any condition precluding the use of melphalan or Thymoglobulin
Any condition not fulfilling inclusion criteria
Unable to undergo leukapheresis because of poor vein access or other reasons
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note